All In Biotech

Drug Trial Radar · NCT03417245

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Mar 1, 2018

Primary completion

Jan 26, 2021

Study completion Jul 14, 2021

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: -To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes. Secondary Objectives: * To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by: * The frequency of spontaneous bleeding episodes. * The frequency of joint bleeding episodes. * Health-related quality of life (HRQOL) in participants \>=17 years of age. * To determine the frequency of bleeding episodes during the onset period. * To determine the safety and tolerability of fitusiran.

Conditions

  • Hemophilia A
  • Hemophilia B

Interventions

  • fitusiranDrug

    by SC injection

  • factor concentratesDrug

    by intravenous (IV) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest
  2. Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest

Locations

64 sites in 19 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 0140

    Little Rock, Arkansas

  • Investigational Site Number 128

    Gainesville, Florida

  • Investigational Site Number 103

    Tampa, Florida

  • Investigational Site Number 102

    Chicago, Illinois

  • Investigational Site Number 119

    New Orleans, Louisiana

  • Investigational Site Number 125

    Ann Arbor, Michigan

  • Investigational Site Number 111

    Las Vegas, Nevada

  • Investigational Site Number 110

    Akron, Ohio

  • Investigational Site Number 6101

    Camperdown, Australia

  • Investigational Site Number 6103

    Murdoch, Australia

  • Investigational Site Number 6104

    Prahran, Australia

  • Investigational Site Number 8604

    Beijing, China

  • Investigational Site Number 8602

    Guangzhou, China

  • Investigational Site Number 8605

    Hangzhou, China

  • Investigational Site Number 8603

    Shanghai, China

  • Investigational Site Number 8601

    Tianjin, China

  • Investigational Site Number 4501

    Copenhagen, Denmark

  • Investigational Site Number 3303

    Lyon, France

  • Investigational Site Number 3305

    Paris, France

  • Investigational Site Number 3301

    Rouen, France

  • Investigational Site Number 4904

    Berlin, Germany

  • Investigational Site Number 4905

    Frankfurt am Main, Germany

  • Investigational Site Number 4906

    Leipzig, Germany

  • Investigational Site Number 3602

    Budapest, Hungary

  • Investigational Site Number 9102

    Bangalore, India

  • Investigational Site Number 9104

    Jaipur, India

  • Investigational Site Number 9106

    Lucknow, India

  • Investigational Site Number 9109

    Mumbai, India

  • Investigational Site Number 9108

    Mumbai, India

  • Investigational Site Number 9111

    Mumbai, India

  • Investigational Site Number 9103

    Pune, India

  • Investigational Site Number 9105

    Vellore, India

  • Investigational Site Number 9701

    Ramat Gan, Israel

  • Investigational Site Number 3904

    Padova, Italy

  • Investigational Site Number 8105

    Isehara, Japan

  • Investigational Site Number 8104

    Saitama, Japan

  • Investigational Site Number 6004

    Ampang, Malaysia

  • Investigational Site Number 6002

    Johor Bahru, Malaysia

  • Investigational Site Number 6003

    Kota Kinabalu, Malaysia

  • Investigational Site Number 2701

    Parktown, South Africa

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.